Updated on 6 January 2016
Through this acquisition, Eisai has entered the generic pharmaceutical business in China
Singapore: Eisai announced that regarding the acquisition of Chinese generic pharmaceutical company Liaoning TianYi Biological Pharmaceutical previously announced on November 27, 2015, the conditions of transfer have been arranged, including receiving a new business license from the regulatory authority in China, and the acquisition has been completed.
The trading name of Liaoning TianYi Biological Pharmaceutical was changed to "Eisai (Liaoning) Pharmaceutical" (Eisai Liaoning), and the company has become a wholly-owned subsidiary of Eisai China Holdings.
Through this acquisition, Eisai has entered the generic pharmaceutical business in China in addition to expanding its existing business focused on new medicines. By further strengthening its business foundation established over 25 years of doing business in China and providing a stable supply of high quality generic pharmaceuticals, Eisai is able to fulfill an even wider range of medical needs in China.
Eisai will continue to further contribute to increasing the benefits for a greater number of patients and their families throughout China.
In addition, the signing of this agreement will have a minor impact on the consolidated result forecasts for the period ended March 31, 2016.